Seaport Therapeutics (NASDAQ:SPTX) Stock Gets Price Target Bump from JPMorgan Chase & Co.

Posted by Brian Himes on Nov 7th, 2026

Seaport Therapeutics (NASDAQ:SPTX – Get Free Report) had its target price lifted by JPMorgan Chase & Co. from $40.00 to $41.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 90.70% from the stock’s previous close.

Several other research analysts also recently issued reports on SPTX. JonesTrading started coverage on Seaport Therapeutics in a research note on Wednesday, August 26th. They set a “buy” rating and a $32.00 price target for the company. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Seaport Therapeutics in a report on Thursday, October 8th. Canaccord Genuity Group began coverage on shares of Seaport Therapeutics in a report on Wednesday, October 14th. They set a “buy” rating and a $28.00 target price for the company. Raymond James Financial initiated coverage on shares of Seaport Therapeutics in a research report on Friday, September 25th. They set a “strong-buy” rating and a $46.00 target price for the company. Finally, UBS Group reiterated a “buy” rating on shares of Seaport Therapeutics in a research report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $37.12.

Read Our Latest Report on SPTX

Seaport Therapeutics Price Performance

Shares of SPTX traded up $1.11 on Thursday, reaching $21.50. The stock had a trading volume of 227,030 shares, compared to its average volume of 226,115. Seaport Therapeutics has a twelve month low of $14.85 and a twelve month high of $28.38. The stock has a market cap of $1.15 billion and a price-to-earnings ratio of -1.77. The company’s 50-day moving average is $20.68.

Seaport Therapeutics (NASDAQ:SPTX – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.09. As a group, equities analysts anticipate that Seaport Therapeutics will post -4.35 EPS for the current year.

Insider Activity at Seaport Therapeutics

In related news, Director Denice Torres acquired 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 3rd. The stock was purchased at an average price of $19.86 per share, for a total transaction of $99,300.00. Following the transaction, the director owned 5,000 shares in the company, valued at $99,300. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Institutional Investors Weigh In On Seaport Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. TRV GP VI LLC acquired a new stake in Seaport Therapeutics during the second quarter worth approximately $44,769,742. Citadel Advisors LLC purchased a new stake in Seaport Therapeutics in the 2nd quarter worth approximately $4,152,000. The Manufacturers Life Insurance Company acquired a new position in Seaport Therapeutics in the 2nd quarter valued at $1,793,000. State Street Corp acquired a new position in Seaport Therapeutics in the 2nd quarter valued at $1,448,000. Finally, Alyeska Investment Group L.P. acquired a new position in Seaport Therapeutics in the 2nd quarter valued at $1,629,000.

Seaport Therapeutics News Summary

Here are the key news stories impacting Seaport Therapeutics this week:

Positive Sentiment: Director Denice Torres bought 5,000 shares for about $99,300 at an average price of $19.86, a notable insider purchase that may signal confidence in the company. Article: Seaport Therapeutics Director Purchases Shares
Positive Sentiment: JPMorgan raised its price target to $41 from $40 and maintained an Overweight rating. HC Wainwright also reiterated its Buy rating and $50 target, reflecting continued analyst optimism, though targets are not guarantees. Seaport Therapeutics analyst information
Neutral Sentiment: HC Wainwright made mixed earnings-estimate revisions: it narrowed its projected FY2026 loss to $3.95 per share from $4.09 and improved its Q4 2026 and Q1 2027 estimates, but its Q3 and Q4 2027 estimates imply somewhat larger losses. The revisions are modest and do not change its Buy rating or $50 target.
Positive Sentiment: Seaport’s latest reported quarterly loss of $0.49 per share was better than the $0.58 loss analysts expected, providing a recent earnings beat that may help cushion concerns about future losses.

About Seaport Therapeutics

(Get Free Report)

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company uses its Glyph platform, a technology designed to create prodrugs that may improve the delivery, tolerability, and effectiveness of certain therapies, including treatments intended to reach the brain.

Seaport’s pipeline includes investigational therapies for neurological and neuropsychiatric conditions. Its programs have included GTX-102, an oral investigational medicine being developed for Angelman syndrome, a rare genetic neurodevelopmental disorder, as well as additional candidates aimed at addressing unmet needs in CNS care.

The company was established with support from PureTech Health and is headquartered in Boston, Massachusetts.